LETTERS TO THE EDITOR

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages Ibrutinib is an oral irreversible inhibitor of the bruton tyrosine kinase (Btk) which has shown promising efficacy and excellent tolerability in patients with chronic lympho-cytic leukemia (CLL) and other B-cell malignancies.1 Ibrutinib inhibits BCR signaling, impairs chemokine-medi-ated adhesion and migration, and induces moderate levels of apoptosis on CLL cells.2,3 It also reduces TCR down-stream activation on Th2 cells by targeting another kinase, the interleukin-2–inducible kinase (Itk).4 The combinatio